Merck Issues Voluntary Nationwide Recall of CUBICIN ® (Daptomycin for Injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is voluntarily recalling one lot of CUBICIN ® (daptomycin for injection) 500mg for intravenous use, Lot 934778, Exp June 2022. Because treatment with CUBICIN is likely to be initiated at a hospital or other monitored healthcare se

Source: FDA Center for Drug Evaluation and Research - What's New - October 20, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news